Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$887.16 USD

887.16
1,970,679

+1.61 (0.18%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $884.12 -3.04 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Eli Lilly (LLY) Rises Higher Than Market: Key Facts

The latest trading day saw Eli Lilly (LLY) settling at $598.05, representing a +1.66% change from its previous close.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod

AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.

Zacks Market Edge Highlights: SAIC, ANET, LLY, PFE and SIG

SAIC, ANET, LLY, PFE and SIG have been highlighted in this Market Edge article.

Tracey Ryniec headshot

Will There Be a Recession in 2024?

Tracey Ryniec and John Blank examine whether a recession is looming and how to invest in the new year.

Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?

Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.

Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca

Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.

Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B

Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.

Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study

Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.

Pfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II

The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.

Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why

Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.

The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer

AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.

Alexandria (ARE), Eli Lilly to Expand Gateway Labs to San Diego

The expansion of Gateway Labs to San Diego reaffirms the strength and depth of the partnership between Alexandria (ARE) and Eli Lilly.

Kinjel Shah headshot

4 Large Drug Stocks to Watch as IBD Market Gains Traction

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).

Is Invesco Large Cap Growth ETF (PWB) a Strong ETF Right Now?

Smart Beta ETF report for PWB

Kinjel Shah headshot

3 Large Drug Stocks That Have Outperformed Industry YTD

Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Sector ETF report for PJP

The Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce

Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, Accenture & The TJX Companies

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Accenture plc (ACN) and The TJX Companies, Inc. (TJX).

Novo Nordisk (NVO) to Expand Manufacturing Site in France

Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.

Kinjel Shah headshot

Pharma Stock Roundup: NVO & LLY to Expand Manufacturing Capacity in Europe, & More

Eli Lilly (LLY) plans to build a $2.5 billion manufacturing plant in Germany. Novo Nordisk (NVO) plans to invest $2.3 billion to expand an existing production site in France.

Eli Lilly (LLY) Stock Outperforms Industry YTD: Here's Why

Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.

ABBV vs. LLY: Which Stock Should Value Investors Buy Now?

ABBV vs. LLY: Which Stock Is the Better Value Option?